118488-08-7

Basic information

• Product Name: 1-(Thiophen-3-yl)ethanamine
• Synonyms: 1-(3-Thienyl)ethanaMine;1-(THIOPHEN-3-YL)ETHAN-1-AMINE;[1-(Thien-3-yl)ethyl]amine;1-(Thiophen-3-yl)ethanamine;1-(3-thienyl)ethanamine(SALTDATA: FREE);[1-(3-Thienyl)ethyl]amine
• CAS NO: 118488-08-7
• Molecular Formula: C₆H₉NS
• Molecular Weight: 127.21
• Mol File: 118488-08-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 200.242°C at 760 mmHg
• Flash Point: 74.904°C
• Appearance: /
• Density: 1.095g/cm³
• Vapor Pressure: 0.328mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 10.04±0.29(Predicted)
• CAS DataBase Reference: 1-(Thiophen-3-yl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Thiophen-3-yl)ethanamine(118488-08-7)
• EPA Substance Registry System: 1-(Thiophen-3-yl)ethanamine(118488-08-7)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• Hazardous Substances Data: 118488-08-7(Hazardous Substances Data)

Usage

Description

1-(Thiophen-3-yl)ethanamine, also known as 3-(2-Aminoethyl)thiophene, is a chemical compound characterized by a thiophene ring connected to an ethylamine group. It is an amine with the molecular formula C6H9NS and a molar mass of 127.21 g/mol. This colorless to light yellow liquid exhibits a strong, unpleasant odor and is recognized for its diverse biological activities. It plays a significant role in organic synthesis and pharmaceutical research, particularly in the development of potential therapeutics for central nervous system disorders and neurodegenerative diseases. Moreover, 1-(Thiophen-3-yl)ethanamine is a valuable intermediate in the production of other chemicals and pharmaceutical compounds.

Uses

Used in Pharmaceutical Research and Development:
1-(Thiophen-3-yl)ethanamine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a versatile building block for the creation of new drugs with potential applications in treating a range of medical conditions.
Used in Organic Synthesis:
As an amine, 1-(Thiophen-3-yl)ethanamine is utilized in organic synthesis for the preparation of a variety of chemical products. Its reactivity and functional groups make it suitable for use in the formation of complex organic molecules.
Used in the Development of Therapeutics for Central Nervous System Disorders:
1-(Thiophen-3-yl)ethanamine is employed as a starting material in the development of potential therapeutics for central nervous system disorders. Its biological activities and chemical properties make it a promising candidate for the treatment of such conditions.
Used in the Development of Therapeutics for Neurodegenerative Diseases:
Similarly, 1-(Thiophen-3-yl)ethanamine is used in the research and development of therapeutics aimed at treating neurodegenerative diseases. Its potential role in modulating biological pathways relevant to these diseases makes it an important compound in the search for effective treatments.
Used in Chemical Production:
1-(Thiophen-3-yl)ethanamine serves as an intermediate in the production of other chemicals, contributing to the synthesis of a wide range of chemical products across various industries.

InChI:InChI=1/C6H9NS/c1-5(7)6-2-3-8-4-6/h2-5H,7H2,1H3

Upstream product

• 118488-07-6 1-(3-thienyl)ethylazide 
• 1468-83-3 1-(thiophen-3-yl)-ethanone 
• 56423-56-4 3-(1-chloroethyl)thiophene 
• 14861-60-0 1-(thiophen-3-yl)ethan-1-ol 

Relevant articles and documents

Direct reductive amination of ketones with ammonium salt catalysed by Cp*Ir(iii) complexes bearing an amidato ligand

A series of half-sandwich Ir(iii) complexes1-6bearing an amidato bidentate ligand were conveniently synthesized and applied to the catalytic Leuckart-Wallach reaction to produce racemic α-chiral primary amines. With 0.1 mol% of complex1, a broad range of ketones, including aryl ketones, dialkyl ketones, cyclic ketones, α-keto acids, α-keto esters and diketones, could be transformed to their corresponding primary amines with moderate to excellent yields (40%-95%). Asymmetric transformation was also attempted with chiral Ir complexes3-6, and 16% ee of the desired primary amine was obtained. Despite the unsatisfactory enantio-control achieved so far, the current exploration might stimulate more efforts towards the discovery of better chiral catalysts for this challenging but important transformation.

TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.